Tags

Type your tag names separated by a space and hit enter

Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Psychiatry Clin Neurosci. 2009 Apr; 63(2):167-75.PC

Abstract

AIMS

To determine factors for switching to osmotic release oral system methylphenidate (OROS-MPH) among poor adherents to immediate-release methylphenidate (IR-MPH); and to compare the efficacy of OROS-MPH on the three attention-deficit/hyperactivity disorder (ADHD) subtypes in a multi-site prospective observational study in Taiwan.

METHODS

The sample included 240 children with ADHD, aged 6-16 years, who were poor adherents to IR-MPH, 137 of whom were switched to OROS-MPH. The child psychiatrists diagnosed the Diagnostic Statistical Manual of Mental Disorders (4th edition) ADHD subtypes and assessed the medical history, adherence, side-effects, global ADHD severity, and family/school effectiveness. Parents reported their child's behavioral symptoms.

RESULTS

The determinants for an OROS-MPH switch were higher dosage, shorter treatment and thrice-daily administration of IR-MPH, and more severe inattention symptoms. Hyperactivity and oppositional symptoms were greater in the ADHD combined and hyperactive-impulsive subtypes than the inattentive subtype. Switching to OROS-MPH significantly improved behavioral symptoms and family/school measures, and this was most evident in the ADHD-combined group, followed by the ADHD-inattentive group. Inattention influenced not only academic performance, but also overall classroom behaviors and the parent-child relationship, with the latter two also influenced by oppositional symptoms.

CONCLUSIONS

This study suggests better efficacy for the OROS-MPH among poor adherents to IR-MPH; however, its effectiveness varied across the three ADHD subtypes (ClinicalTrials.gov number NCT00460720).

Authors+Show Affiliations

Department of Child Psychiatry, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19335386

Citation

Chou, Wen-Jiun, et al. "Better Efficacy for the Osmotic Release Oral System Methylphenidate Among Poor Adherents to Immediate-release Methylphenidate in the Three ADHD Subtypes." Psychiatry and Clinical Neurosciences, vol. 63, no. 2, 2009, pp. 167-75.
Chou WJ, Chou MC, Tzang RF, et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci. 2009;63(2):167-75.
Chou, W. J., Chou, M. C., Tzang, R. F., Hsu, Y. C., Gau, S. S., Chen, S. J., Wu, Y. Y., Huang, Y. F., Liang, H. Y., & Cheng, H. (2009). Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry and Clinical Neurosciences, 63(2), 167-75. https://doi.org/10.1111/j.1440-1819.2009.01937.x
Chou WJ, et al. Better Efficacy for the Osmotic Release Oral System Methylphenidate Among Poor Adherents to Immediate-release Methylphenidate in the Three ADHD Subtypes. Psychiatry Clin Neurosci. 2009;63(2):167-75. PubMed PMID: 19335386.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. AU - Chou,Wen-Jiun, AU - Chou,Miao-Chun, AU - Tzang,Ruu-Fen, AU - Hsu,Ya-Chen, AU - Gau,Susan Shur-Fen, AU - Chen,Shin-Jaw, AU - Wu,Yu-Yu, AU - Huang,Ya-Fen, AU - Liang,Hsin-Yi, AU - Cheng,Helen, PY - 2009/4/2/entrez PY - 2009/4/2/pubmed PY - 2009/7/16/medline SP - 167 EP - 75 JF - Psychiatry and clinical neurosciences JO - Psychiatry Clin Neurosci VL - 63 IS - 2 N2 - AIMS: To determine factors for switching to osmotic release oral system methylphenidate (OROS-MPH) among poor adherents to immediate-release methylphenidate (IR-MPH); and to compare the efficacy of OROS-MPH on the three attention-deficit/hyperactivity disorder (ADHD) subtypes in a multi-site prospective observational study in Taiwan. METHODS: The sample included 240 children with ADHD, aged 6-16 years, who were poor adherents to IR-MPH, 137 of whom were switched to OROS-MPH. The child psychiatrists diagnosed the Diagnostic Statistical Manual of Mental Disorders (4th edition) ADHD subtypes and assessed the medical history, adherence, side-effects, global ADHD severity, and family/school effectiveness. Parents reported their child's behavioral symptoms. RESULTS: The determinants for an OROS-MPH switch were higher dosage, shorter treatment and thrice-daily administration of IR-MPH, and more severe inattention symptoms. Hyperactivity and oppositional symptoms were greater in the ADHD combined and hyperactive-impulsive subtypes than the inattentive subtype. Switching to OROS-MPH significantly improved behavioral symptoms and family/school measures, and this was most evident in the ADHD-combined group, followed by the ADHD-inattentive group. Inattention influenced not only academic performance, but also overall classroom behaviors and the parent-child relationship, with the latter two also influenced by oppositional symptoms. CONCLUSIONS: This study suggests better efficacy for the OROS-MPH among poor adherents to IR-MPH; however, its effectiveness varied across the three ADHD subtypes (ClinicalTrials.gov number NCT00460720). SN - 1440-1819 UR - https://www.unboundmedicine.com/medline/citation/19335386/Better_efficacy_for_the_osmotic_release_oral_system_methylphenidate_among_poor_adherents_to_immediate_release_methylphenidate_in_the_three_ADHD_subtypes_ L2 - https://doi.org/10.1111/j.1440-1819.2009.01937.x DB - PRIME DP - Unbound Medicine ER -